Dr. Tse-Wen Chang, Founder and Chairman
Please see Founder
Dr. Hsing-Mao Art Chu
Chief Executive Officer, CEO
Dr. Chu earned his bachelor’s degree from Chang Gung University, followed by a master’s degree from National Yang Ming University and a Ph.D. from National Taiwan University. He conducted postdoctoral research at the Institute of Biological Chemistry, Academia Sinica, and in 2011 joined the laboratory of Distinguished Research Fellow Dr. Tse-Wen Chang at the Genomics Research Center, focusing on antibody engineering. His research centered on elucidating the molecular mechanisms underlying the interactions between CεmX and anti-CεmX.
In 2015, Dr. Chu joined Immunwork to lead R&D efforts using the proprietary T-E technology platform, advancing multiple drug programs. He has overseen six proof-of-concept successes, with two candidates entering human clinical trials, and is a co-inventor of more than 90 related patents. In 2023, Dr. Chu was appointed CEO of T-E Meds, while concurrently serving as Vice President of R&D at Immunwork. He currently serves as CEO of T-E Pharma, continuing to lead the company’s R&D and innovation efforts and driving novel drug candidates toward clinical development and commercialization.
Ms. Ying-Rong Lai
Chief Operating Officer, COO
Ms. Lai holds a Master’s degree in Biotechnology Management from National Taiwan University. Throughout her career, she has gained experience across multiple industries, including internal cost control and estimation, participation in industry tenders, and business management. She also spent several years in the higher education sector and engaged in both domestic and international trade, before ultimately entering the financial and accounting sector. She has demonstrated outstanding management experience across various business domains. With over a decade of experience in the financial industry, she has received multiple performance awards during her career.
In 2014, she was invited by Dr. Tse-Wen Chang to join the company’s executive team, assisting in the establishment of Immunwork and overseeing administrative and financial planning. She currently serves as Chief Operating Officer (COO) of T-E Pharma, responsible for company operations and overall management.